Skip to main content

Physician Search

 


Displaying 1 - 1 of 1

First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia

Multiple Cancer Types

This first-in-human (FIH) dose-escalation and dose-validation / expansion study will assess ziftomenib (KO-539), a menin-MLL(KMT2A) inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML).
Leukemia, Phase I
I/II
Strickland, Stephen
NCT04067336
VICCHEMP20122